A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Incyte Corporation
Eilean Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Turin, Italy
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
University of Southern California
Incyte Corporation
University Hospital, Brest
University of Washington
Incyte Corporation
M.D. Anderson Cancer Center
University of California, Irvine
University Hospital, Angers
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
MPN Research Foundation
Brigham and Women's Hospital
Massachusetts General Hospital
University of Miami
Icahn School of Medicine at Mount Sinai
University Hospital, Angers
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
Constellation Pharmaceuticals
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Ohio State University Comprehensive Cancer Center
Hangzhou GluBio Pharmaceutical Co., Ltd.
PharmaEssentia
PharmaEssentia
PharmaEssentia
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
RWTH Aachen University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Italfarmaco
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
AbbVie
IRCCS Azienda Ospedaliero-Universitaria di Bologna
University Hospital, Angers
Tongji Hospital
M.D. Anderson Cancer Center
University Health Network, Toronto
University Hospital, Brest
Astex Pharmaceuticals, Inc.